Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.85 |
| ▸ | DRD4 | P21917 | 3/20 | 0.74 |
| ▸ | DRD3 | P35462 | 3/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884293 | 0.93 | SIGMAR1 (0.75) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL8285657 | 0.92 | SIGMAR1 (1.00) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL1887340 | 0.89 | SIGMAR1 (0.86) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL12673260 | 0.88 | SIGMAR1 (0.83) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL12896039 | 0.85 | SIGMAR1 (0.87) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL8285662 | 0.85 | SIGMAR1 (1.00) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL8284828 | 0.83 | SIGMAR1 (1.00) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL1887377 | 0.82 | SIGMAR1 (0.87) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL1887858 | 0.82 | DRD3 (0.74) | SIGMAR1DRD4DRD3DRD2TMEM97 | |
| SCHEMBL13638098 | 0.81 | SIGMAR1 (0.81) | SIGMAR1DRD4DRD3DRD2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947838-B2 | Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100150836-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150836-A1 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING | TMEM97, SIGMAR1, SFN | SIGMAR1 2/4885DRD4 785/4885DRD3 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.